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Introduction
Coronary artery disease (CAD) and congestive heart failure (CHF) are leading causes of morbidity 
and mortality in Western communities and represent a growing economic burden to most health sys-
tems (Cohn et al. 1997). CHF arises from the process of ventricular remodeling, which can occur in 
response to either ischemic or non-ischemic myocardial insult. Central to this process, is the progres-
sive loss of cardiomyocytes and contractile cardiac tissue. Following severe myocardial infarction 
(MI), large-scale death of cardiomyocytes (approximately 1.8 × 109 cells), occurs via a process of 
ischemic “anoikos”, which is followed by apoptosis of vulnerable cardiomyocytes in peri-infarct ter-
ritories (Murry et al. 2006). Although more sporadic and insidious, substantial cardiomyocyte loss is 
also associated with remodeling in other disease states including hypertension, valvular disease and 
cardiomyopathies.
Current conventional therapy of CHF has evolved from numerous seminal advances over the last 
two decades (Fonarow, 2000). Improvements in pharmacotherapy addressing the neurohormonal changes 
associated with the condition have provided the mainstay of treatment. These advances have been 
accompanied by a concomitant improvement in coronary revascularization techniques, the development 
of cardiac resynchronization pacemakers and implantable defi brillators, more effective immune modu-
lation for heart transplant recipients and increasing usage of mechanical assist devices. With the obvi-
ous exception of cardiac transplantation, these treatment options are limited by their failure to replace 
lost cardiomyocytes and myocardial scar tissue with new, functioning, contractile tissue. This is com-
pounded by the heart’s own incapacity to replace its lost cell mass by self-regeneration. Consequently, 
in its most advanced stages, CHF is associated with an extremely grave prognosis, with six month 
mortality rates approaching 50%, rivalling the most aggressive types of malignancy. New approaches 
to CHF treatment are therefore required.
Cell-based therapy has seen a rapid evolution over the last decade. While much of the ground covered 
has been at the level of basic science through both in vitro and in vivo preclinical research, the last six 
years have also witnessed the application of this novel treatment strategy in clinical trials of MI, CAD 
and cardiomyopathy The fi rst part of this two-part review will address the biological properties and 
functional potential of different cell types that have been trialed in preclinical cardiovascular research. 
Part two will focus on the clinical application of these cells and will discuss the lessons learnt from 
clinical trial experience so far.
Endogenous Myocardial Repair
For many years, the long-standing dogma has been that adult cardiomyocytes undergo terminal differ-
entiation soon after birth, irreversibly withdrawing from the cell cycle. In the postnatal state, uncoupling 
of cardiomyocyte karyokinesis and cytokinesis helps to explain the characteristic cell hypertrophy and 
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nuclear ploidy, rather than hyperplasia, that occurs 
following cardiac injury (Kellerman et al. 1992). 
Furthermore, the inability of cardiomyocytes to 
progress through the cell cycle contributes to their 
apoptosis. In recent years, however, this long-held 
depiction of the adult mammalian heart as a post-
mitotic organ has been severely challenged. It is 
now apparent that not all cardiomyocytes in the 
adult heart lose their ability to replicate. Initially 
this was inferred from observations that there is an 
increase in the number of proliferating cardiac cells 
after MI, especially in the peri-infarct territories, 
but also in areas of remote, non-infarcted myocar-
dium (Beltrami et al. 2001). Similar evidence of 
cell division is also evident in cardiac failure 
(Kajstura et al. 1998). These fi ndings prompted 
investigations into the properties and the functional 
role of these dividing cells under both normal tissue 
homeostasis and pathological conditions.
Circulating non-cardiac cells
Evidence that extrinsic (non-cardiac) cells may 
contribute to endogenous cardiac repair processes 
emerged from transplantation studies in which 
donor and recipient organs were sex mismatched 
and small numbers of Y-chromosome containing 
cells were identifi ed in the female donor hearts of 
male transplant recipients (Lafl amme et al. 2002). 
This implied the migration of a non-resident cell 
type(s) to the heart which contributed to resident 
endothelial and possibly cardiomyocyte cell 
populations. It is now well established that in 
response to myocardial insult, a variety of mature 
and immature cell types are mobilized from 
non-cardiac organs, such as bone marrow (BM), 
into peripheral blood to assist with cardiac and 
vascular repair. These cells include lymphocytes, 
monocytes/macrophages, granulocytes, mature 
endothelial cells along with progenitor cells such 
as endothelial progenitor cells (EPCs), hemato-
poietic stem cells (HSCs) and mesenchymal stem 
cells (MSCs) (Mouquet et al. 2005; Wojakowski 
et al. 2007). Following acute MI, peripheral blood 
levels of CD34+ EPCs rise in association with 
plasma levels of vascular endothelial growth fac-
tor (VEGF), peak within just a few hours and 
remain elevated throughout the fi rst week (Shintani 
et al. 2001; Massa et al. 2005). Different sub-
populations of mobilized progenitor cells have also 
been identified, specifically: CD34+/CD117+, 
CD34+/CXCR4+, CD34+/CD38+ and CD34+/CD45+ 
cells (Wojakowski et al. 2007). Activation of che-
mokines and chemokine receptors, such as stro-
mal-derived factor-1 (SDF-1; CXCL12) and its 
receptor CXCR4, play central roles in the mobili-
zation of these cells and their migration to, and 
engraftment in, the injured myocardium (Askari 
et al. 2003).
Cardiac resident progenitor cells
In addition to the recruitment of non-cardiac stem 
cells, there is exciting evidence from several 
groups, demonstrating the existence of resident 
cardiac stem/progenitor cells in the hearts of adult 
mammalian species, including humans (Beltrami 
et al. 2003; Oh et al. 2003; Laugwitz et al. 2005). 
Different techniques have been used to identify 
populations of these cells, including co-expression 
of stem cell markers (c-kit, SCA-1, Islet-1, MDR1) 
with cardiac and vascular-associated markers. It is 
not clear whether these subtypes of cardiac stem 
cells are actually distinct from each other or merely 
represent different stages of normal cardiomyocyte 
development. However, each has shown capacity 
for cardiomyocyte differentiation both in vitro and 
in vivo and in some cases differentiation into endo-
thelial and smooth muscle cell lineages as well 
(Beltrami et al. 2003; Moretti et al. 2006).
While not fully characterized, cardiac stem cells 
may occupy niches within atrial tissue, the atrio-
ventricular groove and the apical ventricular myo-
cardium, where they form structural and functional 
connections to mature cardiomyocytes and cardiac 
fi broblasts (Messina et al. 2004; Urbanek et al. 
2006). Growth factors, such as insulin-derived 
growth factor (IGF-1) and hepatocyte growth fac-
tor (HGF), appear able to stimulate their migration 
to sites of injury and their proliferation and 
differentiation into mature cardiac and vascular-
specifi c cells. Unfortunately, these responses are 
severely attenuated in the hostile environment of 
acute MI and cardiac remodeling, implying that 
under these conditions myocardial cell loss goes 
largely unreplaced, limiting the heart’s capacity 
for self-repair.
The existence of these native stem cell popula-
tions does however, provide evidence for an endog-
enous cardiac repair process that can be targeted 
by exogenous cells or factors to reduce cardiac 
remodeling and aid myocardial healing. There is 
also the exciting potential for the therapeutic appli-
cation of these autologous cardiac stem cells which 
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could be harvested by endomyocardial biopsy and 
then reimplanted into damaged tissue. Indeed pre-
clinical studies investigating this promising strat-
egy are well underway (Oh et al. 2003; Beltrami 
et al. 2003; Messina et al. 2004; Dawn et al. 2005; 
Smith et al. 2007).
Exogenous Cell Therapy 
for Cardiac Repair
Following initial proof-of-concept studies using 
fetal cardiomyocytes transplanted into fi brotic 
myocardial scars (Leor et al. 1996), various other 
cell types have been examined for their capacity to 
mediate cardiac and vascular repair, in both in vitro 
assays and in vivo transplantation studies.
Stem cells are defi ned by their ability to achieve 
self-renewal, high replicative potential and the 
capacity to differentiate into multiple mature cell 
types. Stem cells can be classifi ed into two broad 
types: embryonic stem cells (ESCs) and adult-
derived stem cells (ASCs). Embryonic stem cells 
are totipotent with the ability to develop all the 
tissue-forming cells that constitute an entire organ-
ism, while ASCs reside in the postnatal state in 
tissue niches and function to replenish cell loss as 
a consequence of tissue damage and death. The 
differentiation potential of some ASC populations 
is not only confi ned to the cells of their specifi c 
tissue of origin, but to other cell lineages as well. 
As detailed below, not all of the cell types applied 
to cardiac therapy fulfi ll these criteria for stem 
cells.
Embryonic stem cells
Embryonic stem cells are derived from the inner 
cell mass of the blastocyst. They display promising 
preclinical potential for achieving myocardial 
regeneration, largely as a result of their enormous 
proliferative capacity and their toti–differentiation 
potential. There are numerous reports in the litera-
ture describing the properties of both murine ESC 
(mESC) lines and human ESCs (hESCs), which 
were fi rst successfully isolated from human blas-
tocysts in 1998 and have consistently shown car-
diogenic potential in vitro (Thomson et al. 1998; 
Kehat et al. 2001; He et al. 2003; Kehat et al. 2004). 
Human ESC-derived cardiomyocytes behave 
structurally and functionally like early-stage car-
diomyocytes, expressing characteristic early cell 
markers and possessing electrophysiological and 
ultrastructural features similar to fetal ventricular 
cardiomyocytes. Cardiac-committed cells can be 
enriched from hESC culture using Percoll gradient 
centrifugation. Initial studies, in which these cells 
were transplanted into animal models of heart 
disease, demonstrated their durable engraftment, 
proliferation and differentiation in vivo, and impor-
tantly, their integration with host cardiomyocytes 
(Xue et al. 2005; Lafl amme et al. 2005).
Unfortunately, current techniques for isolating 
and generating differentiated hESC-derived CMCs 
for clinical use are limited by issues of yield and 
failure to exclude undifferentiated ESCs. The latter 
issue poses signifi cant risk of teratoma formation 
at sites of cell transplantation or in other tissues 
following migration of immature ESCs to second-
ary sites. Along with tumor risk, immunorejection 
and ethico-legal considerations are currently major 
obstacles hindering the clinical application of 
hESCs (Lafl amme and Murry, 2005). While these 
problems are not insurmountable, the emerging 
fi eld of nuclear transfer technology provides an 
appealing future alternative to hESC therapy 
(Lanza et al. 2004).
Adult cells
Various adult tissues contain resident cell popula-
tions that have been tested in cardiac research. 
Most experience has involved cells from skeletal 
muscle, bone marrow and blood, however, other 
tissue sites, such as adipose, dental pulp and peri-
odontal ligament, placental and umbilical cord 
blood and of course the heart itself, also harbour 
cell types that are being intensively investigated.
Skeletal myoblasts
Skeletal myoblasts (SkMs) are committed skeletal 
muscle precursor cells that normally lie in a qui-
escent state under the basal lamina of skeletal 
muscle fi bers. Their normal role is to regenerate 
skeletal muscle following injury, both by fusion 
with the surrounding muscle fi ber and by differen-
tiation into contractile mature skeletal myocytes. 
Autologous SkMs are easily accessible through 
muscle biopsy and can be rapidly expanded in vitro 
to high cell number for therapeutic application. 
In vitro isolation can be assisted through their 
expression of the surface marker CD56. Of rele-
vance to cardiac repair, these cells remain commit-
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A number of preclinical studies have demonstrated 
that these cells can engraft, proliferate and survive 
in the presence of various forms of myocardial 
injury, ultimately improving systolic and diastolic 
cardiac function (Marelli et al. 1992; Taylor et al. 
1998; He et al. 2005; Hata et al. 2006). The mech-
anisms responsible for these functional benefi ts are 
unlikely to be related to myoblast transdifferentia-
tion into cardiomyocytes. Studies have documented 
consistently that these cells fail to adopt a cardiac 
phenotype after their engraftment into the myocar-
dium (Reinecke et al. 2002). These cells therefore 
remain committed to their skeletal muscle origin 
in vivo, but may change over time to become 
more fatigue resistant, by acquiring a greater com-
ponent of slow-fi ber myosin. They also fail to 
electromechanically couple with host cardiomyocytes 
through the production of gap junction and the 
intercalated disc proteins, N-cadherin and 
connexin-43 (Reinecke et al. 2000). This phenom-
enon may partly explain the electrical instability, 
manifested by ventricular tachyarrhythmias, that 
complicated transplantation of SkMs in early 
clinical studies (Menasche et al. 2003). In the 
absence of cardiac transdifferentiaton and 
electromechanical coupling, SkMs may mediate 
cardiac repair through various other mechanisms, 
including autonomous contraction, infarct size 
reduction and stabilization of scar tissue. They may 
also infl uence cardiac remodeling and angiogenesis 
in a paracrine fashion by the release of cytokines 
and growth factors such as VEGF and HGF 
(Chazaud et al. 2003). Numerous clinical studies 
have addressed the therapeutic potential of skele-
tal myoblasts in ischemic (post-infarction) 
cardiomyopathy.
Bone marrow and blood-derived cells
Bone marrow and peripheral blood contain various 
types of progenitor/stem cells, with the best defi ned 
being hematopoietic stem cells (HSCs), angioblasts 
and endothelial progenitor cells (EPCs) and mes-
enchymal stem cells (MSCs). Numerous subpopu-
lations of these cell types have been identifi ed 
through techniques such as fl ow cytometric analy-
sis, although in many cases they are still incom-
pletely characterized.
Unfractionated bone marrow
A paucity of comparative studies between the dif-
ferent types of BM-derived stem cells has created 
uncertainty as to which cell-type is optimal for 
cardiac repair. Many trials, especially those in 
humans, have avoided the use of specifi c stem cell 
fractions, preferring to adopt a “blanket” treatment 
approach by administering unfractionated bone 
marrow cells (BMCs) or bone marrow mononuclear 
cells (BMMNCs). These preparations are hetero-
geneous in their cellular composition and include 
monocytes, lymphocytes, nucleated red cells, 
immature B- and T-cells and a minor proportion of 
HSCs (2.5%) and MSCs (0.0001%) (Gronthos 
and Simmons, 1995; Gronthos et al. 2003).
Unfractionated bone marrow cells have been 
transplanted in preclinical models of ischemic and 
non-ischemic cardiomyopathy, with the most 
notable benefi ts relating to improvements in myo-
cardial vascularisation (Fuchs et al. 2001; Agbulut 
et al. 2003; Silva et al. 2005). In clinical studies, 
the practicality of using unfractionated BM has 
been well suited to acute MI, where the time 
required to prepare autologous stem cells (e.g. 
MSCs) can preclude cell delivery in the early stages 
of infarct healing. While the low frequency of 
clonogenic stem cells in BM may limit its repara-
tive potential, this limitation may be counterbal-
anced by the pleiotropic properties inherent in 
using a mixture of immature and mature cell types. 
Comparative studies between unfractionated 
BMCs/BMMNCs and fractionated stem cell 
populations are required to provide scientifi c ratio-
nale to the relative merits of both treatment 
approaches.
Hematopoietic stem cells
Subtypes of HSCs have been investigated in pre-
clinical models of myocardial injury, with incon-
sistent results. A seminal study by Orlic et al. 
directly injected murine Lin-c-kitpos BM-derived 
cells into mice post MI (Orlic et al. 2001). These 
cells were labeled to express enhanced green fl uo-
rescent protein and were observed to engraft into 
the host myocardium within a few days after trans-
plantation. Some engrafted cells exhibited features 
suggestive of cardiomyocyte differentiation and 
animals receiving these cell preparations exhibited 
improvement in invasive hemodynamic measure-
ments of left ventricular function. While similar 
studies have also supported the in vivo engraftment 
and differentiation of HSC subpopulations into 
cardiomyocytes and endothelial cells (Jackson 
et al. 2001), these results have not been consistently 
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reproducible (Murry et al. 2004; Balsam et al. 
2004). Reports have also suggested that apparent 
changes in HSC phenotype may be due to fusion 
with surrounding cells in the host tissue, rather than 
true transdifferentiation (Nygren et al. 2004).
Endothelial progenitor cells
Endothelial precursors capable of transforming 
into mature, functional endothelial cells can be 
isolated from the mononuclear population of either 
BM or peripheral blood. Although bone marrow-
derived EPCs are CD45-lin-, they appear to share 
common ancestry with HSCs, as indicated by their 
expression of the immature hematopoietic markers 
CD34 and CD133, along with vascular endothelial 
growth factor (VEGF) receptor 2 (VEGFR2) 
(or fetal liver kinase-1 [fl k-1]). Upon maturation 
to endothelial cells, CD133 expression is lost and 
replaced by expression of VE-cadherin (CD144), 
CD31 (PECAM-1) and von Willebrand factor 
(vWF) (Peichev et al. 2000; Masuda and Asahara, 
2003). At least three subpopulations of EPCs, at 
different stages of maturation and with different 
profi les of CD34 and CD133 expression, are pres-
ent in the peripheral blood. These circulating cells 
are derived from both CD117+/VEGFR+ BM 
hemangioblasts and peripheral blood monocytes. 
In recent years, highly proliferative EPCs have also 
been isolated from umbilical cord blood (Ingram 
et al. 2004).
As discussed previously, EPCs are mobilized 
into the peripheral circulation as part of the normal 
physiologic response to tissue ischemia and vas-
cular injury, allowing their migration to the site of 
injury under the infl uence of growth factors, such 
as VEGF and SDF-1. There they contribute to 
neovascularization, by differentiation into mature 
endothelial cells, incorporation into new vessels 
(vasculogenesis) and promotion of local vascular 
cell growth (angiogenesis) (Asahara et al. 1997). 
The numbers of circulating progenitor cells fl uctu-
ate in response to ischemic injury (e.g. MI) and are 
also infl uenced by other factors, including the pres-
ence of cardiovascular risk factors and non-cardiac 
diseases, ageing and specific pharmacologic 
agents, such as HMG-CoA reductase inhibitors 
(Isner, 2000; Shintani et al. 2001; Llevadot et al. 
2001).
As the frequency of EPCs is very low in BM 
(CD34+ ~2% and CD133+ ~0.5% of total cells) and 
even more so in peripheral blood, therapeutic 
application has usually necessitated their isolation 
by ex vivo expansion of MNCs on fi bronectin-
coated tissue plates. Two distinct subpopulations 
of EPCs result – early outgrowth and late out-
growth populations – with different capacities for 
further culture and proliferation (Ingram et al. 
2004; Young et al. 2007). Both populations have 
been successfully trialed in animal models of 
hindlimb ischemia, achieving viable engraftment 
and promoting new vessel formation. Combined 
administration of the early and late outgrowth 
populations may optimize these pro-vascular 
effects (Lee et al. 2005).
Preclinical studies of cell transplantation post-
MI, have demonstrated pro-angiogenic and anti-
apoptotic benefits of angioblasts and EPCs, 
culminating in improved myocardial function 
(Schuh et al. 2007). These effects are probably 
mediated by a combination of improved local tis-
sue perfusion and protective paracrine effects that 
EPCs exert on dying cardiomyocytes (Kocher et al. 
2001; Rehman et al. 2003; Schuster et al. 2004). 
There is also limited in vitro experience indicating 
that EPCs may be able to undergo cardiomyocyte 
differentiation (Badorff et al. 2003).
Mesenchymal stem cells
This rare type of stem cell is found both in BM and 
other tissues, including adipose tissue, dental pulp, 
periodontal ligament, umbilical cord blood and 
placenta (Gronthos et al. 2001; Shi and Gronthos, 
2003; Rangappa et al. 2003; Kogler et al. 2004; 
Kim et al. 2005; Miao et al. 2006). Typically in 
these tissues, MSCs are located in perivascular 
niches surrounding blood vessels, where they play 
an important supportive role for other cell types. 
Their important contribution to the creation and 
maintenance of stromal and skeletal tissues in BM 
has led to the use of interchangeable terminology, 
such as somatic stem cells, stromal stem cells and 
marrow stromal cells.
Traditionally, BMMSCs are isolated from the 
MNC fraction based on their adherence to tissue 
culture plastic and the subsequent formation of 
colonies of spindle-shaped cells (colony-forming-
units-fibroblastic: CFU-F) (Friedenstein et al. 
1970). Clonogenic MSCs possess the proliferative 
potential to enable them to be expanded ex vivo to 
the high cell numbers required for transplantation. 
These cells have distinct surface molecule 
expression to other BM-derived stem cells; they 
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are CD34− and CD45− but stain positively for a 
range of other markers, including SH2 (CD 105), 
SH4 (CD 73), CD49d,e, CD71, CD106 and CD166 
(Pittenger et al. 1999; Bianco et al. 2001).
Plasticity of MSCs isolated from BM and other 
tissues, is classically demonstrated by differentia-
tion into adipoblasts, chondroblasts and osteoblasts 
under appropriate culture conditions (Bianco et al. 
2001). Of more relevance to potential cardiac 
application, these cells also have potential to 
acquire phenotypic characteristics of cardiomyo-
cytes, smooth muscle cells and endothelial cells, 
prompting expectation that they may be able to 
provide both myogenic and vasculogenic benefi ts 
to injured myocardium (Galmiche et al. 1993; 
Makino et al. 1999; Toma et al. 2002; Shim et al. 
2004; Xu et al. 2004; Iwase et al. 2005; Silva et al. 
2005).
There is a large body of preclincial research 
confi rming the pro-myogenic and pro-angiogenic 
properties of non-induced, ex vivo expanded 
BMMSCs in various animal models of cardiac 
injury (Toma et al. 2002; Nagaya et al. 2004; 
Hattan et al. 2005; Amado et al. 2005; Silva et al. 
2005; Hou et al. 2006). Studies examining the 
effi cacy of transplantating MSCs post-infarction 
have consistently reported attenuation of myocar-
dial scarring and infarct size, improved regional 
and global ventricular function and increased vas-
cular density and in some cases myocardial perfu-
sion (Shake et al. 2002; Amado et al. 2005). 
Restoration of myocardial mechano-energetics has 
also been observed and may be an important 
mechanism by which MSC therapy can avert post-
MI heart failure (Amado et al. 2005). Benefi cial 
effects on myocardial vascularization appear to be 
largely mediated indirectly through cytokine and 
growth factor release, although potential for MSC 
engraftment into blood vessels and differentiation 
into endothelial and smooth muscle cells has also 
been demonstrated (Davani et al. 2003; Kinnaird 
et al. 2004a; Silva et al. 2005). While most pre-
clinical studies have not demonstrated signifi cant 
adverse observations at MSC injection sites, a 
recent study in a murine model of cryo-infarction 
reported a high incidence (approximately 50%) of 
encapsulated areas containing ossifi cations and/or 
calcifi cations in tissue that had received MSC 
transplantation (Breitbach et al. 2007). This fi nding 
highlights the need for all preclinical studies to be 
thorough in their assessment of adverse histo-
pathological outcomes from cellular therapy.
In addition to their pro-myogenic and pro-
angiogenic potential, MSCs are also hypoimmu-
nogenic, enabling them to exist in infl ammatory 
environments without activating host T-lympho-
cytes (Ruggeri et al. 2001). These immune proper-
ties are partly due to a lack of surface expression 
of MHC Class II molecules and co-stimulatory 
molecules for T-cell induction (CD40, CD40 
ligand, and the B7 molecules CD80 and CD86) 
(Tse et al. 2003; Le Blanc et al. 2003). Mesenchy-
mal stem cells down-regulate lymphocyte prolif-
eration and suppress the maturation and function 
of various other immune cells. This occurs both by 
direct cell contact of MSCs with these target cells 
and also by the release of immune-modifying 
soluble factors, such as HGF, interleukin-10 and 
prostaglandin E (PGE)-2 (Kuroiwa et al. 2001; 
Rasmusson et al. 2005; Aggarwal and Pittenger, 
2005). The culmination of these immune-modifying 
effects raises the potential for MSCs to be used 
allogeneically without concurrent immunosuppres-
sion. This may have major clinical advantages, as 
an allogeneic “off-the-shelf” or “ready-to-use” 
source of MSCs would enable early MSC trans-
plantation after MI. It also promises to avoid the 
shortcomings of autologous cell therapy, especially 
in elderly patients with chronic diseases (e.g. CAD, 
CHF), who characteristically have impaired stem 
cell recovery, proliferation and function (Heeschen 
et al. 2004). Clinical application of allo-MSCs 
awaits careful comparative studies with autologous 
MSCs.
Mechanisms of Benefi t 
from Cell Therapy
Early in vitro and in vivo evidence that specifi c cell 
types could differentiate into cardiomyocytes gave 
rise to an expectation that exogenous stem cells 
might be capable of regenerating injured myocar-
dium, by direct replacement of the cells that are 
lost during cardiac remodeling. Increasingly, the 
potential for current cell strategies to achieve actual 
cardiomyocyte regeneration appears at best lim-
ited. Cardiac transdifferentiation has not been 
observed with SkMs, despite their capacity to 
improve myocardial function in animal studies. In 
addition, evidence for in vivo cardiac transforma-
tion of other cell types, has largely been based on 
immunofl uorescence and immunohistochemical 
analyses which are prone to tissue artefact and also 
do not reliably account for the possible confounder 
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of cell fusion (Terada et al. 2002; Nygren et al. 
2004). Cell labeling and imaging techniques have 
been developed to track the fate of transplanted 
cells in vivo, consistently showing that engraftment 
of cells is modest, with as few as 0%–6% still 
present in the recipient heart soon after direct car-
diac injection (Hou et al. 2005; Freyman et al. 
2006). This refl ects poorly on the early retention 
and longer-term engraftment and survival of cells 
in disease states such as MI and cardiomyopathy 
and unfortunately has not yet been overcome 
by using alternative routes of cell delivery or by 
administering higher doses of cells. These observa-
tions suggest that current approaches to cell therapy 
fall short of fulfi lling the objective of actual myo-
cardial regeneration and instead facilitate cardiac 
repair through alternative mechanisms.
Recent studies have acknowledged that para-
crine actions underlie much of the cardiac repara-
tive effects of transplanted cells, including their 
ability to increase angiogenesis, reduce infarct size 
and ventricular wall thinning and improve myo-
cardial contractility (Kamihata et al. 2001; Kinnaird 
et al. 2004c; Tang et al. 2005b). Mesenchymal stem 
cells, EPCs, HSCs and SkMs possess the potential 
to infl uence other cells in their vicinity, by direct 
cell-to-cell interaction and by release of a wide 
array of soluble growth factors and cytokines. 
These soluble factors are influenced by the 
developmental status and properties of the trans-
planted cell populations and by the local milieu in 
which the cells fi nd themselves (Weimar et al. 
1998; Caplan and Dennis, 2006). Growth factors 
that have been identifi ed as possibly contributing 
to myocardial and vascular repair include SDF-1, 
HGF, IGF-1, basic fi broblast growth factor (bFGF), 
VEGF, angiopoeitin-1 (Ang-1), monocyte che-
moattractant protein 1 (MCP-1), interleukins-1 and 
6, placental growth factor, plasminogen activator 
and tumor necrosis factor-alpha (TNF-α) (Kamihata 
et al. 2001; Kinnaird et al. 2004b).
In the injured myocardium, transplanted cells 
may exert paracrine actions on a range of resident 
mature and immature cell types, facilitating 
endogenous repair processes. This may include 
protection of stressed cardiomyocytes that are vul-
nerable to apoptosis in peri-infarct areas, and pro-
mitogenic and homing effects on cardiac progenitor 
cells, endothelial cells and endothelial progenitor 
cells. The latter contributes to neovascularization, 
which in turn further supports the viability of donor 
and host cells, especially in the presence of isch-
emia. Although such paracrine effects of cell therapy 
may be only part of the mechanism of benefi t in 








Cell Fusion Perivascular Incorporation
NeovascularizationPassive Effects on Scar
Proliferation & Reduced Apoptosis 
of Endogenous Cells
Stem/Progenitor Cells
Figure 1. Mechanisms by which cell therapy may achieve cardiovascular repair.
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Selecting the Optimal Cell Type
Presently uncertainty exists as to which cell types 
are best-suited for the treatment of different cardiac 
pathologies. Cell-based treatment can theoretically 
benefi t the injured heart either by new blood vessel 
formation or improvement in myocardial systolic 
and/or diastolic function. Different cell types vary 
in their ability to infl uence these two broad mech-
anisms. In the context of myocardial ischemia, 
where the objective is reperfusion, the more favor-
able cells are those that can enhance angiogenesis 
and neovascularization. Cells derived from bone 
marrow (BM) or peripheral blood (PB) fall into 
this category, such as BMMNCs (Stamm et al. 
2003), MSCs (Silva et al. 2005), BM angioblasts 
(Itescu et al. 2002), EPCs (Assmus et al. 2002; 
Rauscher et al. 2003), or multipotent adult pro-
genitor cells (MAPCs) (Jiang et al. 2002). In situ-
ations where cardiac dysfunction predominates, 
such as in cardiomyopathy or after severe MI, cell 
types which can induce myogenesis, reduce 
myocardial wall stress and perhaps stabilize myo-
cardial scar will be of most value. Examples 
include skeletal myoblasts (SkMs), MSCs and cells 
from the heart  i tself ,  including mature 
cardiomyocytes, cardiac fi broblasts and cardiac 
stem cells.
Currently there is a paucity of research expe-
rience comparing the effectiveness of these dif-
ferent cell types. In preclinical models of cardiac 
injury, transplantation of SkMs has been com-
pared with fetal cardiomyocytes (Scorsin et al. 
2000), fi broblasts (Hutcheson et al. 2000) and 
bone marrow-derived cells, including MSCs and 
CD133+ EPCs (Thompson et al. 2003; Agbulut 
et al. 2004; Guarita-Souza et al. 2006a). In each 
of these studies, SkM therapy was shown to 
improve cardiac systolic performance, in a man-
ner superior to fi broblasts and EPCs and non-
inferior when compared to other BM cell 
preparations
The relative merits of combination versus 
individual cell therapy are also unresolved. Com-
bination therapy can be achieved by transplanting 
two or more cell populations together which may 
be especially attractive in ischemic cardiomy-
opathy, where cardiac dysfunction is associated 
with poor tissue perfusion. Examples include the 
co-transplantation of BMMNCs and SkMs in a 
rat study of MI (Ott et al. 2004) and the co-admin-
istration of SkMs and MSCs in a murine model 
of Chagas cardiomyopathy (Guarita-Souza et al. 
2006b). Alternatively, cell therapy can be com-
bined with coronary revascularization, either by 
percutaneous intervention (Schachinger et al. 
2006) or coronary artery bypass surgery (CABG) 
(Menasche et al. 2001), in order to enhance the 




Despite great optimism, signifi cant challenges 
remain before cell therapies can be used widely in 
clinical practice (Chien, 2004; Oettgen et al. 2006). 
Unresolved clinical issues relate to optimal cell 
dose, delivery technique, timing of delivery and 
monitoring of long-term effi cacy and safety out-
comes, including cell fate. Critical work also 
remains for basic science to improve our under-
standing of stem cell biology so that this can be 
manipulated to ultimately optimize clinical out-
comes. Major ongoing areas of preclinical research 
and development include: (1). cell isolation and 
purifi cation and (2). in vitro manipulation of cell 
therapy by gene and growth factor regulation or 
biomaterial scaffolds.
Preparation and purifi cation
Optimization of cell isolation and culture tech-
niques may be an important step towards maximiz-
ing both the effi cacy and safety of cell therapies. 
As indicated above, isolation procedures for 
differentiated hESCs will be critical for minimizing 
tumor risk with these cells. Traditional techniques 
to prepare adult cell types are also imperfect. The 
limited supply of progenitor cells from BM and 
peripheral blood could potentially be overcome by 
using alternative tissue sources, such as adipose, 
which contain a higher number of clonogenic cells 
from freshly prepared tissue (Zannettino et al. 
2007).
Historically, BMMSC culture has involved the 
plastic adherence of MNCs and ex vivo expansion 
of the cell progeny. Cell purity has been claimed 
on the grounds that the resulting MSCs express 
certain surface antigens, despite the fact that these 
antigens are neither specifi c nor defi nitive markers 
of cells with bona fi de stem cell properties. Colo-
nies isolated by plastic adherence of MNCs are 
known to be heterogeneous, containing both imma-
ture multipotent MSCs, but also a significant 
number of contaminating cell types such as more 
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mature mesenchymal cells (e.g. osteoblasts, osteo-
progenitor cells, fat cells and fibroblasts) and 
non-mesenchymal cells (e.g. macrophages and 
endothelial cells) (Simmons and Torok-Storb, 
1991; Alhadlaq and Mao, 2004). In addition, when 
ex vivo expanded to achieve adequate cell numbers 
for transplantation, MSC progeny lose their stem 
cell qualities, including their capacity for prolif-
eration and differentiation.
Techniques have emerged to counter these 
limitations inherent with MSC preparation by 
plastic adherence and ex vivo expansion. They 
include prospective immunoselection and clonal 
expansion of single cells. Immunoselection refers 
to selection of cells based on their negative or 
positive expression of specifi c surface antigens. 
Antibodies that have been used to enrich for MSCs 
include STRO-1, VCAM-1(CD106) and STRO-3 
(Simmons and Torok-Storb, 1991; Gronthos et al. 
2003; Gronthos et al. 2007). Human MSCs 
expressing high levels of STRO-1, an as yet 
unidentifi ed antigen, possess many hallmark char-
acteristics of immature stem cells and achieved 
impressive cardiac protection and neovasculariza-
tion when applied to a rat model of MI (Kortesidis 
et al. 2005; Martens et al. 2006). Immunoselection 
has also been used for the preparation of CXCR4+ 
blood-derived cells, based on strong evidence that 
CXCR4 and its ligand SDF-1 play a crucial role 
in the mobilization and homing of circulating cells 
to the heart (Petit et al. 2007).
Distinct subpopulations of adult BM progeni-
tor cells, derived from clonal expansion, include 
multipotent adult progenitor cells (“MAPCs”), 
“snMSCs” and “hBMSCs”. Each of these have 
been applied to promising effect in preclinical 
studies of cardiac therapy (Reyes et al. 2001; 
Jiang et al. 2002). Multipotent adult progenitor 
cells and hBMSCs appear to possess ESC proper-
ties of extensive proliferative capacity and toti-
potent differentiation into all three germ cell 
layers. Recently, another group has been able to 
induce ESC-like stem cells by retroviral transduc-
tion of differentiated somatic cells (dermal fi bro-
blasts) with specifi c transcription factors (Oct3/4, 
Sox2, c-Myc and Klf4) (Yamanaka and Takahashi, 
2006; Takahashi et al. 2007). Although the bio-
logical properties of these adult-derived cells 
appear very favorable for tissue repair, uncertainty 
remains as to whether these pluripotent cell types 
are vulnerable to dysregulated mutations and 
tumorigenesis.
In vitro manipulation
There is considerable interest in combining cel-
lular therapy with other strategies to overcome the 
current problems of insuffi cient engraftment and 
survival of transplanted cells in the heart. Culture 
and transplantation of cells in carefully designed 
bio-scaffolds could potentially achieve enhance-
ment of adhesion, growth, and migration signals 
in vivo, while simultaneously providing structural 
and mechanical support to the damaged cardiac 
region (Davis et al. 2005). Genetic engineering has 
also been used to impart cytoprotective effects to 
newly transplanted cells, so that the effi ciency of 
cell therapy is enhanced. Examples include trans-
fection of cells with genes encoding the anti-
apoptotic factor Akt (Mangi et al. 2003), fi broblast 
growth factor-2 (FGF-2) (Song et al. 2005) and 
angiopoietin (Jiang et al. 2006). Manipulation of 
MSCs to overexpress Akt has resulted in further 
enhancement of the reparative effects of MSC 
therapy in animal models of infarction, both with 
respect to global left ventricular ejection fraction 
and also area of infarct scarring (Mangi et al. 2003; 
Gnecchi et al. 2005; Lim et al. 2006). This may 
partly refl ect greater resistance of Akt-transfected 
cells to in vivo apoptosis, but in addition has also 
been shown to relate to stronger paracrine effects 
that these cells may impart to the host myocardium 
(Gnecchi et al. 2006).
Mesenchymal stem cells have also been modi-
fi ed using a hypoxia-regulated heme oxygenase-1 
(HO-1) plasmid vector which increased short-term 
cell survival by fi ve-fold in a murine study of MI. 
This survival advantage was accompanied by ben-
efi ts in reducing the infarct size and improved 
cardiac function (Tang et al. 2005a). Another 
popular candidate gene for pre-transplant cell 
modification has been VEGF. Transfection of 
various cell types with plasmids encoding this gene 
has become an alternative to direct gene therapy 
which has had some promising results in animal 
and human studies of coronary ischemia (Rosen-
gart et al. 1999; Vale et al. 2001). The combined 
cell/gene therapy approach may provide longer-
lasting overexpression of VEGF and its angiogenic 
effects than can be achieved with gene only therapy 
(Yau et al. 2001; Matsumoto et al. 2005). However, 
the safety of this approach remains uncertain due 
to concerns of late vascular tumor formation (Lee 
et al. 2000).
SDF-1 plays a crucial role in traffi cking of pro-
genitor cells from the bone marrow to ischemic 
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tissue (Ceradini et al. 2004) and consequently some 
experimental strategies have attempted to upregulate 
its effects in myocardial ischemia. Pre-transplanta-
tion engineering of cardiac fi broblasts (Askari et al. 
2003) and mesenchymal stem cells (Zhang et al. 
2007) has resulted in enhancement of myocardial 
repair and cardiomyocyte preservation in rodent 
studies, while another successful approach has been 
to precondition MSCs by adding SDF-1 to the cell 
culture media during in vitro expansion (Pasha et 
al. 2007). Administration of exogenous SDF-1 in 
the absence of concomitant cell transplantation has 
resulted in mixed outcomes, with one porcine study 
showing deleterious effects on left ventricular func-
tion following intramyocardial SDF-1 injection two 
weeks after MI (Koch et al. 2006).
Conclusion
There is now a large body of preclinical evidence 
supporting the potential for a variety of cell types 
to facilitate cardiac and vascular repair. Currently, 
adult-derived cells appear limited in their capacity 
to achieve true replacement of damaged and/or dead 
cardiomyocytes and their benefi cial effects appear 
to be predominantly reparative. Much of this car-
diac repair seems to be mediated through indirect 
or paracrine actions of these cells on endogenous 
tissues and cell populations. Although more capable 
of proliferating and differentiating to the extent 
required to replace the cells lost in cardiac disease 
states than their adult counterparts, embryonic stem 
cells have a number of inherent challenges before 
becoming a viable clinical alternative.
Optimizing techniques by which cells used for 
transplantation are isolated, cultured and manipu-
lated in vitro will play a crucial role in improving 
the engraftment and function of these cells in vivo. 
Equally important in achieving clinical application 
will be the issues of tailoring specifi c cell types to 
specifi c myocardial diseases and delivering cells to 
the heart both safely and effi ciently. However, the 
potential of cell-based therapies to provide a para-
digm shift in the clinical management of patients 
with heart failure, demands continued research.
References
Agbulut, O., Menot, M.L., Li, Z., Marotte, F., Paulin, D., Hagege, A.A., 
Chomienne, C., Samuel, J.L. and Menasche, P. 2003. Temporal pat-
terns of bone marrow cell differentiation following transplantation 
in doxorubicin-induced cardiomyopathy. Cardiovascular research, 
58:451–9.
Agbulut, O., Vandervelde, S., Al Attar, N., Larghero, J., Ghostine, S., 
Leobon, B., Robidel, E., Borsani, P., Le Lorc’h, M., Bissery, A., 
Chomienne, C., Bruneval, P., Marolleau, J.P., Vilquin, J.T., 
Hagege, A., Samuel, J.L. and Menasche, P. 2004. Comparison of 
human skeletal myoblasts and bone marrow-derived CD133+ pro-
genitors for the repair of infarcted myocardium. Journal of the 
American College of Cardiology, 44:458–63.
Aggarwal, S. and Pittenger, M.F. 2005. Human mesenchymal stem cells 
modulate allogeneic immune cell responses. Blood, 105:1815–22.
Alhadlaq, A. and Mao, J.J. 2004. Mesenchymal stem cells: isolation and 
therapeutics. Stem Cells Dev., 13:436–48.
Amado, L.C., Saliaris, A.P., Schuleri, K.H., St John, M., Xie, J.S., 
Cattaneo, S., Durand, D.J., Fitton, T., Kuang, J.Q., Stewart, G., 
Lehrke, S., Baumgartner, W.W., Martin, B.J., Heldman, A.W. and 
Hare, J.M. 2005. Cardiac repair with intramyocardial injection of 
allogeneic mesenchymal stem cells after myocardial infarction. 
Proceedings of the National Academy of Sciences of the United States 
of America, 102:11474–9.
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., 
Witzenbichler, B., Schatteman, G. and Isner, J.M. 1997. Isolation of 
putative progenitor endothelial cells for angiogenesis. Science, 
275:964–7.
Askari, A.T., Unzek, S., Popovic, Z.B., Goldman, C.K., Forudi, F., 
Kiedrowski, M., Rovner, A., Ellis, S.G., Thomas, J.D., DiCorleto, P.E., 
Topol, E.J. and Penn, M.S. 2003. Effect of stromal-cell-derived fac-
tor 1 on stem-cell homing and tissue regeneration in ischaemic 
cardiomyopathy. Lancet, 362:697–703.
Assmus, B., Schachinger, V., Teupe, C., Britten, M., Lehmann, R., 
Dobert, N., Grunwald, F., Aicher, A., Urbich, C., Martin, H., 
Hoelzer, D., Dimmeler, S. and Zeiher, A.M. 2002. Transplantation 
of Progenitor Cells and Regeneration Enhancement in Acute Myo-
cardial Infarction (TOPCARE-AMI). Circulation, 106:3009–17.
Badorff, C., Brandes, R.P., Popp, R., Rupp, S., Urbich, C., Aicher, A., 
Fleming, I., Busse, R., Zeiher, A.M. and Dimmeler, S. 2003. Transdif-
ferentiation of blood-derived human adult endothelial progenitor cells 
into functionally active cardiomyocytes. Circulation, 107:1024–32.
Balsam, L.B., Wagers, A.J., Christensen, J.L., Kofi dis, T., Weissman, I.L. and 
Robbins, R.C. 2004. Haematopoietic stem cells adopt mature haema-
topoietic fates in ischaemic myocardium. Nature, 428:668–73.
Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., 
Kasahara, H., Rota, M., Musso, E., Urbanek, K., Leri, A., Kajstura, J., 
Nadal-Ginard, B. and Anversa, P. 2003. Adult cardiac stem cells are 
multipotent and support myocardial regeneration. Cell, 114:763–76.
Beltrami, A.P., Urbanek, K., Kajstura, J., Yan, S.M., Finato, N., Bussani, R., 
Nadal-Ginard, B., Silvestri, F., Leri, A., Beltrami, C.A. and Anversa, P. 
2001. Evidence that human cardiac myocytes divide after myocardial 
infarction. The New England journal of medicine, 344:1750–7.
Bianco, P., Riminucci, M., Gronthos, S. and Robey, P.G. 2001. Bone marrow 
stromal stem cells: nature, biology, and potential applications. Stem 
Cells, 19:180–92.
Breitbach, M., Bostani, T., Roell, W., Xia, Y., Dewald, O., Nygren, J.M., 
Fries, J.W., Tiemann, K., Bohlen, H., Hescheler, J., Welz, A., Bloch, 
W., Jacobsen, S.E. and Fleischmann, B.K. 2007. Potential risks of 
bone marrow cell transplantation into infarcted hearts. Blood, 
110:1362–9.
Caplan, A.I. and Dennis, J.E. 2006. Mesenchymal stem cells as trophic 
mediators. J. Cell Biochem., 98:1076–84.
Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., 
Kleinman, M.E., Capla, J.M., Galiano, R.D., Levine, J.P. and 
Gurtner, G.C. 2004. Progenitor cell traffi cking is regulated by hypoxic 
gradients through HIF-1 induction of SDF-1. Nature medicine, 
10:858–64.
Chazaud, B., Sonnet, C., Lafuste, P., Bassez, G., Rimaniol, A.C., Poron, F., 
Authier, F.J., Dreyfus, P.A. and Gherardi, R.K. 2003. Satellite cells 
attract monocytes and use macrophages as a support to escape apop-
tosis and enhance muscle growth. J. Cell Biol., 163:1133–43.
Chien, K.R. 2004. Stem cells: lost in translation. Nature, 428:607–8.
135
Cellular therapy for cardiovascular disease
Clinical Medicine: Cardiology 2008:2 
Cohn, J.N., Bristow, M.R., Chien, K.R., Colucci, W.S., Frazier, O.H., 
Leinwand, L.A., Lorell, B.H., Moss, A.J., Sonnenblick, E.H., 
Walsh, R.A., Mockrin, S.C. and Reinlib, L. 1997. Report of the 
National Heart, Lung, and Blood Institute Special Emphasis Panel 
on Heart Failure Research. Circulation, 95:766–70.
Davani, S., Marandin, A., Mersin, N., Royer, B., Kantelip, B., Herve, P., 
Etievent, J.P. and Kantelip, J.P. 2003. Mesenchymal progenitor cells 
differentiate into an endothelial phenotype, enhance vascular density, 
and improve heart function in a rat cellular cardiomyoplasty model. 
Circulation, 108 Suppl(1):II253–8.
Davis, M.E., Hsieh, P.C., Grodzinsky, A.J. and Lee, R.T. 2005. Custom 
design of the cardiac microenvironment with biomaterials. Circula-
tion research, 97:8–15.
Dawn, B., Stein, A.B., Urbanek, K., Rota, M., Whang, B., Rastaldo, R., Torella, D., 
Tang, X.L., Rezazadeh, A., Kajstura, J., Leri, A., Hunt, G., Varma, J., 
Prabhu, S.D., Anversa, P. and Bolli, R. 2005. Cardiac stem cells delivered 
intravascularly traverse the vessel barrier, regenerate infarcted myocardium, 
and improve cardiac function. Proceedings of the National Academy of 
Sciences of the United States of America, 102:3766–71.
Fonarow, G.C. 2000. Heart failure: recent advances in prevention and treat-
ment. Rev. Cardiovasc. Med., 1, 54:25–33.
Freyman, T., Polin, G., Osman, H., Crary, J., Lu, M., Cheng, L., Palasis, M. 
and Wilensky, R.L. 2006. A quantitative, randomized study evaluat-
ing three methods of mesenchymal stem cell delivery following 
myocardial infarction. Eur. Heart J., 27:1114–22.
Friedenstein, A.J., Chailakhjan, R.K. and Lalykina, K.S. 1970. The develop-
ment of fi broblast colonies in monolayer cultures of guinea-pig bone 
marrow and spleen cells. Cell Tissue Kinet., 3:393–403.
Fuchs, S., Baffour, R., Zhou, Y.F., Shou, M., Pierre, A., Tio, F.O., 
Weissman, N.J., Leon, M.B., Epstein, S.E. and Kornowski, R. 2001. 
Transendocardial delivery of autologous bone marrow enhances 
collateral perfusion and regional function in pigs with chronic 
experimental myocardial ischemia. Journal of the American College 
of Cardiology, 37:1726–32.
Galmiche, M.C., Koteliansky, V.E., Briere, J., Herve, P. and Charbord, P. 
1993. Stromal cells from human long-term marrow cultures are 
mesenchymal cells that differentiate following a vascular smooth 
muscle differentiation pathway. Blood, 82:66–76.
Gnecchi, M., He, H., Liang, O.D., Melo, L.G., Morello, F., Mu, H., 
Noiseux, N., Zhang, L., Pratt, R.E., Ingwall, J.S. and Dzau, V.J. 2005. 
Paracrine action accounts for marked protection of ischemic heart by 
Akt-modifi ed mesenchymal stem cells. Nature medicine, 11:367–8.
Gnecchi, M., He, H., Noiseux, N., Liang, O.D., Zhang, L., Morello, F., 
Mu, H., Melo, L.G., Pratt, R.E., Ingwall, J.S. and Dzau, V.J. 2006. 
Evidence supporting paracrine hypothesis for Akt-modifi ed mesen-
chymal stem cell-mediated cardiac protection and functional improve-
ment. Faseb. J., 20:661–9.
Gronthos, S., Fitter, S., Diamond, P., Simmons, P., Itescu, S. and Zannettino, 
ACW. 2007. A Novel Monoclonal Antibody (STRO-3) Identifi es an 
Isoform of Tissue Nonspecifi c Alkaline Phosphatase Expressed by 
Multipotential Bone Marrow Stromal Stem Cells. Stem Cells and 
Development, 16:
Gronthos, S., Franklin, D.M., Leddy, H.A., Robey, P.G., Storms, R.W. and 
Gimble, J.M. 2001. Surface protein characterization of human adipose 
tissue-derived stromal cells. J. Cell Physiol., 189:54–63.
Gronthos, S. and Simmons, P.J. 1995. The growth factor requirements of 
STRO-1-positive human bone marrow stromal precursors under 
serum-deprived conditions in vitro. Blood, 85:929–40.
Gronthos, S., Zannettino, A.C., Hay, S.J., Shi, S., Graves, S.E., Kortesidis, A. 
and Simmons, P.J. 2003. Molecular and cellular characterisation of 
highly purifi ed stromal stem cells derived from human bone marrow. 
J. Cell Sci., 116:1827–35.
Guarita-Souza, L.C., Carvalho, K.A., Rebelatto, C., Senegaglia, A., 
Hansen, P., Furuta, M., Miyague, N., Francisco, J.C., Olandoski, M., 
Faria-Neto, J.R., Oliveira, S.A. and Brofman, P.R. 2006a. Cell. 
transplantation: Differential effects of myoblasts and mesenchymal 
stem cells. International journal of cardiology, 111:423–9.
Guarita-Souza, L.C., Carvalho, K.A., Woitowicz, V., Rebelatto, C., 
Senegaglia, A., Hansen, P., Miyague, N., Francisco, J.C., Olandoski, M., 
Faria-Neto, J.R. and Brofman, P. 2006b. Simultaneous autologous 
transplantation of cocultured mesenchymal stem cells and skeletal 
myoblasts improves ventricular function in a murine model of Cha-
gas disease. Circulation, 114:I120–4.
Hata, H., Matsumiya, G., Miyagawa, S., Kondoh, H., Kawaguchi, N., 
Matsuura, N., Shimizu, T., Okano, T., Matsuda, H. and Sawa, Y. 2006. 
Grafted skeletal myoblast sheets attenuate myocardial remodeling in 
pacing-induced canine heart failure model. J. Thorac. Cardiovasc. 
Surg., 132:918–24.
Hattan, N., Kawaguchi, H., Ando, K., Kuwabara, E., Fujita, J., Murata, M., 
Suematsu, M., Mori, H. and Fukuda, K. 2005. Purifi ed cardiomyo-
cytes from bone marrow mesenchymal stem cells produce stable 
intracardiac grafts in mice. Cardiovascular research, 65:334–44.
He, K.L., Yi, G.H., Sherman, W., Zhou, H., Zhang, G.P., Gu, A., Kao, R., 
Haimes, H.B., Harvey, J., Roos, E., White, D., Taylor, D.A., Wang, J. 
and Burkhoff, D. 2005. Autologous skeletal myoblast transplantation 
improved hemodynamics and left ventricular function in chronic 
heart failure dogs. J. Heart Lung Transplant., 24:1940–9.
Heeschen, C., Lehmann, R., Honold, J., Assmus, B., Aicher, A., Walter, D.H., 
Martin, H., Zeiher, A.M. and Dimmeler, S. 2004. Profoundly reduced 
neovascularization capacity of bone marrow mononuclear cells 
derived from patients with chronic ischemic heart disease. Circula-
tion, 109:1615–22.
Hou, D., Youssef, E.A., Brinton, T.J., Zhang, P., Rogers, P., Price, E.T., 
Yeung, A.C., Johnstone, B.H., Yock, P.G. and March, K.L. 2005. 
Radiolabeled cell distribution after intramyocardial, intracoronary, 
and interstitial retrograde coronary venous delivery: implications for 
current clinical trials. Circulation, 112:I150–6.
Hou, M., Yang, K.M., Zhang, H., Zhu, W.Q., Duan, F.J., Wang, H., 
Song, Y.H., Wei, Y.J. and Hu, S.S. 2006. Transplantation of mesen-
chymal stem cells from human bone marrow improves damaged heart 
function in rats. International journal of cardiology.
Hutcheson, K.A., Atkins, B.Z., Hueman, M.T., Hopkins, M.B., Glower, D.D. 
and Taylor, D.A. 2000. Comparison of benefi ts on myocardial per-
formance of cellular cardiomyoplasty with skeletal myoblasts and 
fi broblasts. Cell Transplant, 9:359–68.
Ingram, D.A., Mead, L.E., Tanaka, H., Meade, V., Fenoglio, A., Mortell, K., 
Pollok, K., Ferkowicz, M.J., Gilley, D. and Yoder, M.C. 2004. Iden-
tifi cation of a novel hierarchy of endothelial progenitor cells using 
human peripheral and umbilical cord blood. Blood, 104:2752–60.
Isner, J.M. 2000. Tissue responses to ischemia: local and remote responses 
for preserving perfusion of ischemic muscle. J. Clin. Invest, 
106:615–9.
Itescu, S., Kocher, A.A. and Schuster, M.D. 2002. Myocardial neovascu-
larization by adult bone marrow-derived angioblasts: strategies for 
improvement of cardiomyocyte function. Ann. Hematol. 81 Suppl 
2:S21–5.
Iwase, T., Nagaya, N., Fujii, T., Itoh, T., Murakami, S., Matsumoto, T., 
Kangawa, K. and Kitamura, S. 2005. Comparison of angiogenic 
potency between mesenchymal stem cells and mononuclear cells 
in a rat model of hindlimb ischemia. Cardiovascular research, 
66:543–51.
Jackson, K.A., Majka, S.M., Wang, H., Pocius, J., Hartley, C.J., Majesky, M.W., 
Entman, M.L., Michael, L.H., Hirschi, K.K. and Goodell, M.A. 2001. 
Regeneration of ischemic cardiac muscle and vascular endothelium by 
adult stem cells. J. Clin. Invest., 107:1395–402.
Jiang, S., Haider, H.K., Idris, N.M., Salim, A. and Ashraf, M. 2006. Sup-
portive Interaction Between Cell. Survival Signaling and Angiocom-
petent Factors Enhances Donor Cell. Survival and Promotes 
Angiomyogenesis for Cardiac Repair. Circulation research.
Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., 
Ortiz-Gonzalez, X.R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., 
Du, J., Aldrich, S., Lisberg, A., Low, W.C., Largaespada, D.A. and 
Verfaillie, C.M. 2002. Pluripotency of mesenchymal stem cells 
derived from adult marrow. Nature, 418:41–9.
136
Psaltis et al
Clinical Medicine: Cardiology 2008:2 
Kajstura, J., Leri, A., Finato, N., Di Loreto, C., Beltrami, C.A. and Anversa, P. 
1998. Myocyte proliferation in end-stage cardiac failure in humans. 
Proceedings of the National Academy of Sciences of the United States 
of America, 95:8801–5.
Kamihata, H., Matsubara, H., Nishiue, T., Fujiyama, S., Tsutsumi, Y., 
Ozono, R., Masaki, H., Mori, Y., Iba, O., Tateishi, E., Kosaki, A., 
Shintani, S., Murohara, T., Imaizumi, T. and Iwasaka, T. 2001. 
Implantation of bone marrow mononuclear cells into ischemic myo-
cardium enhances collateral perfusion and regional function via side 
supply of angioblasts, angiogenic ligands, and cytokines. Circulation, 
104:1046–52.
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, M., 
Gepstein, A., Livne, E., Binah, O., Itskovitz-Eldor, J. and Gepstein, 
L. 2001. Human embryonic stem cells can differentiate into myocytes 
with structural and functional properties of cardiomyocytes. J. Clin. 
Invest., 108:407–14.
Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., 
Huber, I., Satin, J., Itskovitz-Eldor, J. and Gepstein, L. 2004. Elec-
tromechanical integration of cardiomyocytes derived from human 
embryonic stem cells. Nat. Biotechnol., 22:1282–9.
Kellerman, S., Moore, J.A., Zierhut, W., Zimmer, H.G., Campbell, J. and 
Gerdes, A.M. 1992. Nuclear DNA content and nucleation patterns in 
rat cardiac myocytes from different models of cardiac hypertrophy. 
J. Mol. Cell Cardiol., 24:497–505.
Kim, B.O., Tian, H., Prasongsukarn, K., Wu, J., Angoulvant, D., Wnendt, S., 
Muhs, A., Spitkovsky, D. and Li, R.K. 2005. Cell. transplantation 
improves ventricular function after a myocardial infarction: a pre-
clinical study of human unrestricted somatic stem cells in a porcine 
model. Circulation, 112:I96–104.
Kinnaird, T., Stabile, E., Burnett, M.S. and Epstein, S.E. 2004a. Bone-
marrow-derived cells for enhancing collateral development: mecha-
nisms, animal data, and initial clinical experiences. Circulation 
research, 95:354–63.
Kinnaird, T., Stabile, E., Burnett, M.S., Lee, C.W., Barr, S., Fuchs, S. and 
Epstein, S.E. 2004b. Marrow-derived stromal cells express genes 
encoding a broad spectrum of arteriogenic cytokines and promote in 
vitro and in vivo arteriogenesis through paracrine mechanisms. 
Circulation research, 94:678–85.
Kinnaird, T., Stabile, E., Burnett, M.S., Shou, M., Lee, C.W., Barr, S., 
Fuchs, S. and Epstein, S.E. 2004c. Local delivery of marrow-derived 
stromal cells augments collateral perfusion through paracrine 
mechanisms. Circulation, 109:1543–9.
Koch, K.C., Schaefer, W.M., Liehn, E.A., Rammos, C., Mueller, D., 
Schroeder, J., Dimassi, T., Stopinski, T. and Weber, C. 2006. Effect 
of catheter-based transendocardial delivery of stromal cell-derived 
factor 1alpha on left ventricular function and perfusion in a porcine 
model of myocardial infarction. Basic Res. Cardiol., 101:69–77.
Kocher, A.A., Schuster, M.D., Szabolcs, M.J., Takuma, S., Burkhoff, D., 
Wang, J., Homma, S., Edwards, N.M. and Itescu, S. 2001. Neovas-
cularization of ischemic myocardium by human bone-marrow-derived 
angioblasts prevents cardiomyocyte apoptosis, reduces remodeling 
and improves cardiac function. Nature medicine, 7:430–6.
Kogler, G., Sensken, S., Airey, J.A., Trapp, T., Muschen, M., Feldhahn, N., 
Liedtke, S., Sorg, R.V., Fischer, J., Rosenbaum, C., Greschat, S., 
Knipper, A., Bender, J., Degistirici, O., Gao, J., Caplan, A.I., 
Colletti, E.J., Almeida-Porada, G., Muller, H.W., Zanjani, E. and 
Wernet, P. 2004. A new human somatic stem cell from placental cord 
blood with intrinsic pluripotent differentiation potential. The Journal 
of experimental medicine, 200:123–35.
Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T. and 
Gronthos, S. 2005. Stromal-derived factor-1 promotes the growth, 
survival, and development of human bone marrow stromal stem cells. 
Blood, 105:3793–801.
Kuroiwa, T., Kakishita, E., Hamano, T., Kataoka, Y., Seto, Y., Iwata, N., 
Kaneda, Y., Matsumoto, K., Nakamura, T., Ueki, T., Fujimoto, J. and 
Iwasaki, T. 2001. Hepatocyte growth factor ameliorates acute graft-
versus-host disease and promotes hematopoietic function. J. Clin. 
Invest., 107:1365–73.
Lafl amme, M.A., Gold, J., Xu, C., Hassanipour, M., Rosler, E., Police, S., 
Muskheli, V. and Murry, C.E. 2005. Formation of human myocardium 
in the rat heart from human embryonic stem cells. Am. J. Pathol., 
167:663–71.
Lafl amme, M.A. and Murry, C.E. 2005. Regenerating the heart. Nat. Bio-
technol., 23:845–56.
Lafl amme, M.A., Myerson, D., Saffi tz, J.E. and Murry, C.E. 2002. Evidence 
for cardiomyocyte repopulation by extracardiac progenitors in trans-
planted human hearts. Circulation research, 90:634–40.
Lanza, R., Moore, M.A., Wakayama, T., Perry, A.C., Shieh, J.H., 
Hendrikx, J., Leri, A., Chimenti, S., Monsen, A., Nurzynska, D., 
West, M.D., Kajstura, J. and Anversa, P. 2004. Regeneration of the 
infarcted heart with stem cells derived by nuclear transplantation. 
Circulation research, 94:820–7.
Laugwitz, K.L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodard, S., 
Lin, L.Z., Cai, C.L., Lu, M.M., Reth, M., Platoshyn, O., Yuan, J.X., 
Evans, S. and Chien, K.R. 2005. Postnatal isl1+ cardioblasts enter 
fully differentiated cardiomyocyte lineages. Nature, 433:647–53.
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. and Ringden, O. 2003. 
HLA expression and immunologic properties of differentiated and 
undifferentiated mesenchymal stem cells. Exp. Hematol., 31:890–6.
Lee, N., Thorne, T., Losordo, D.W. and d Yoon, Y.S. 2005. Repair of isch-
emic heart disease with novel bone marrow-derived multipotent stem 
cells. Cell Cycle, 4:861–4.
Lee, R.J., Springer, M.L., Blanco-Bose, W.E., Shaw, R., Ursell, P.C. and 
Blau, H.M. 2000. VEGF gene delivery to myocardium: deleterious 
effects of unregulated expression. Circulation, 102:898–901.
Leor, J., Patterson, M., Quinones, M.J., Kedes, L.H. and Kloner, R.A. 1996. 
Transplantation of fetal myocardial tissue into the infarcted myocar-
dium of rat. A potential method for repair of infarcted myocardium? 
Circulation, 94:II332–6.
Lim, S.Y., Kim, Y.S., Ahn, Y., Jeong, M.H., Hong, M.H., Joo, S.Y., Nam, K.I., 
Cho, J.G., Kang, P.M. and Park, J.C. 2006. The effects of mesenchy-
mal stem cells transduced with Akt in a porcine myocardial infarction 
model. Cardiovascular research, 70:530–42.
Llevadot, J., Murasawa, S., Kureishi, Y., Uchida, S., Masuda, H., 
Kawamoto, A., Walsh, K., Isner, J.M. and Asahara, T. 2001. 
HMG-CoA reductase inhibitor mobilizes bone marrow--derived 
endothelial progenitor cells. J. Clin. Invest., 108:399–405.
Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., 
Sano, M., Takahashi, T., Hori, S., Abe, H., Hata, J., Umezawa, A. and 
Ogawa, S. 1999. Cardiomyocytes can be generated from marrow 
stromal cells in vitro. J. Clin. Invest, 103:697–705.
Mangi, A.A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J.S. and 
Dzau, V.J. 2003. Mesenchymal stem cells modifi ed with Akt prevent 
remodeling and restore performance of infarcted hearts. Nature 
medicine, 9:1195–201.
Marelli, D., Desrosiers, C., el-Alfy, M., Kao, R.L. and Chiu, R.C. 1992. 
Cell. transplantation for myocardial repair: an experimental approach. 
Cell Transplant, 1:383–90.
Martens, T.P., See, F., Schuster, M.D., Sondermeijer, H.P., Hefti, M.M., 
Zannettino, A., Gronthos, S., Seki, T. and Itescu, S. 2006. Mesenchymal 
lineage precursor cells induce vascular network formation in ischemic 
myocardium. Nat. Clin. Pract Cardiovasc. Med. 3 Suppl , 1:S18–22.
Massa, M., Rosti, V., Ferrario, M., Campanelli, R., Ramajoli, I., Rosso, R., 
De Ferrari, G.M., Ferlini, M., Goffredo, L., Bertoletti, A., Klersy, C., 
Pecci, A., Moratti, R. and Tavazzi, L. 2005. Increased circulating 
hematopoietic and endothelial progenitor cells in the early phase of 
acute myocardial infarction. Blood, 105:199–206.
Masuda, H. and Asahara, T. 2003. Post-natal endothelial progenitor cells 
for neovascularization in tissue regeneration. Cardiovascular 
research, 58:390–8.
Matsumoto, R., Omura, T., Yoshiyama, M., Hayashi, T., Inamoto, S., 
Koh, K.R., Ohta, K., Izumi, Y., Nakamura, Y., Akioka, K., Kitaura, Y., 
Takeuchi, K. and Yoshikawa, J. 2005. Vascular endothelial growth 
factor-expressing mesenchymal stem cell transplantation for the 
treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. 
Biol., 25:1168–73.
137
Cellular therapy for cardiovascular disease
Clinical Medicine: Cardiology 2008:2 
Menasche, P., Hagege, A.A., Scorsin, M., Pouzet, B., Desnos, M., Duboc, D., 
Schwartz, K., Vilquin, J.T. and Marolleau, J.P. 2001. Myoblast trans-
plantation for heart failure. Lancet, 357:279–80.
Menasche, P., Hagege, A.A., Vilquin, J.T., Desnos, M., Abergel, E., Pouzet, B., 
Bel, A., Sarateanu, S., Scorsin, M., Schwartz, K., Bruneval, P., 
Benbunan, M., Marolleau, J.P. and Duboc, D. 2003. Autologous skeletal 
myoblast transplantation for severe postinfarction left ventricular dys-
function. Journal of the American College of Cardiology, 41:1078–83.
Messina, E., De Angelis, L., Frati, G., Morrone, S., Chimenti, S., 
Fiordaliso, F., Salio, M., Battaglia, M., Latronico, M.V., Coletta, M., 
Vivarelli, E., Frati, L., Cossu, G. and Giacomello, A. 2004. Isolation 
and expansion of adult cardiac stem cells from human and murine 
heart. Circulation research, 95:911–21.
Miao, Z., Jin, J., Chen, L., Zhu, J., Huang, W., Zhao, J., Qian, H. and 
Zhang, X. 2006. Isolation of mesenchymal stem cells from human 
placenta: Comparison with human bone marrow mesenchymal stem 
cells. Cell. Biol. Int.,
Moretti, A., Caron, L., Nakano, A., Lam, J.T., Bernshausen, A., Chen, Y., 
Qyang, Y., Bu, L., Sasaki, M., Martin-Puig, S., Sun, Y., Evans, S.M., 
Laugwitz, K.L. and Chien, K.R. 2006. Multipotent embryonic isl1+ 
progenitor cells lead to cardiac, smooth muscle, and endothelial cell 
diversifi cation. Cell, 127:1151–65.
Mouquet, F., Pfi ster, O., Jain, M., Oikonomopoulos, A., Ngoy, S., Summer, R., 
Fine, A. and Liao, R. 2005. Restoration of cardiac progenitor cells after 
myocardial infarction by self-proliferation and selective homing of bone 
marrow-derived stem cells. Circulation research, 97:1090–2.
Murry, C.E., Reinecke, H. and Pabon, L.M. 2006. Regeneration gaps: 
observations on stem cells and cardiac repair. Journal of the Ameri-
can College of Cardiology, 47:1777–85.
Murry, C.E., Soonpaa, M.H., Reinecke, H., Nakajima, H., Nakajima, H.O., 
Rubart, M., Pasumarthi, K.B., Virag, J.I., Bartelmez, S.H., Poppa, V., 
Bradford, G., Dowell, J.D., Williams, D.A. and Field, L.J. 2004. 
Haematopoietic stem cells do not transdifferentiate into cardiac 
myocytes in myocardial infarcts. Nature, 428:664–8.
Nagaya, N., Fujii, T., Iwase, T., Ohgushi, H., Itoh, T., Uematsu, M., 
Yamagishi, M., Mori, H., Kangawa, K. and Kitamura, S. 2004. Intra-
venous administration of mesenchymal stem cells improves cardiac 
function in rats with acute myocardial infarction through angiogen-
esis and myogenesis. American journal of physiology, 287:2670–6.
Nygren, J.M., Jovinge, S., Breitbach, M., Sawen, P., Roll, W., Hescheler, J., 
Taneera, J., Fleischmann, B.K. and Jacobsen, S.E. 2004. Bone mar-
row-derived hematopoietic cells generate cardiomyocytes at a low 
frequency through cell fusion, but not transdifferentiation. Nature 
medicine, 10:494–501.
Oettgen, P., Boyle, A.J., Schulman, S.P. and Hare, J.M. 2006. Controversies 
in cardiovascular medicine. Circulation, 114:353–8.
Oh, H., Bradfute, S.B., Gallardo, T.D., Nakamura, T., Gaussin, V., 
Mishina, Y., Pocius, J., Michael, L.H., Behringer, R.R., Garry, D.J., 
Entman, M.L. and Schneider, M.D. 2003. Cardiac progenitor cells 
from adult myocardium: homing, differentiation, and fusion after 
infarction. Proceedings of the National Academy of Sciences of the 
United States of America, 100:12313–8.
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S.M., Li, B., 
Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D.M., Leri, A. and 
Anversa, P. 2001. Bone marrow cells regenerate infarcted myocar-
dium. Nature, 410:701–5.
Ott, H.C., Bonaros, N., Marksteiner, R., Wolf, D., Margreiter, E., 
Schachner, T., Laufer, G. and Hering, S. 2004. Combined transplan-
tation of skeletal myoblasts and bone marrow stem cells for myocar-
dial repair in rats. Eur. J. Cardiothorac. Surg., 25:627–34.
Pasha, Z., Wang, Y., Sheikh, R., Zhang, D., Zhao, T. and Ashraf, M. 2007. 
Preconditioning enhances cell survival and differentiation of stem 
cells during transplantation in infarcted myocardium. Cardiovascular 
research.
Peichev, M., Naiyer, A.J., Pereira, D., Zhu, Z., Lane, W.J., Williams, M., Oz, M.C., 
Hicklin, D.J., Witte, L., Moore, M.A. and Rafi i, S. 2000. Expression of 
VEGFR.-2 and AC133 by circulating human CD34(+) cells identifi es a 
population of functional endothelial precursors. Blood, 95:952–8.
Petit, I., Jin, D. and Rafi i, S. 2007. The SDF-1-CXCR.4 signaling pathway: 
a molecular hub modulating neo-angiogenesis. Trends Immunol., 
28:299–307.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., 
Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S. and 
Marshak, D.R. 1999. Multilineage potential of adult human mesen-
chymal stem cells. Science, 284:143–7.
Rangappa, S., Fen, C., Lee, E.H., Bongso, A. and Sim, E.K. 2003. Trans-
formation of adult mesenchymal stem cells isolated from the fatty 
tissue into cardiomyocytes. Ann. Thorac. Surg., 75:775–9.
Rasmusson, I., Ringden, O., Sundberg, B. and Le Blanc, K. 2005. Mesen-
chymal stem cells inhibit lymphocyte proliferation by mitogens and 
alloantigens by different mechanisms. Exp. Cell Res., 305:33–41.
Rauscher, F.M., Goldschmidt-Clermont, P.J., Davis, B.H., Wang, T., 
Gregg, D., Ramaswami, P., Pippen, A.M., Annex, B.H., Dong, C. and 
Taylor, D.A. 2003. Aging, progenitor cell exhaustion, and atheroscle-
rosis. Circulation, 108:457–63.
Rehman, J., Li, J., Orschell, C.M. and March, K.L. 2003. Peripheral blood 
“endothelial progenitor cells” are derived from monocyte/macro-
phages and secrete angiogenic growth factors. Circulation, 
107:1164–9.
Reinecke, H., MacDonald, G.H., Hauschka, S.D. and Murry, C.E. 2000. 
Electromechanical coupling between skeletal and cardiac muscle. 
Implications for infarct repair. J. Cell Biol., 149:731–40.
Reinecke, H., Poppa, V. and Murry, C.E. 2002. Skeletal muscle stem cells 
do not transdifferentiate into cardiomyocytes after cardiac grafting. 
J. Mol. Cell Cardiol., 34:241–9.
Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L. and Verfaillie, C.M. 
2001. Purifi cation and ex vivo expansion of postnatal human marrow 
mesodermal progenitor cells. Blood, 98:2615–25.
Rosengart, T.K., Lee, L.Y., Patel, S.R., Sanborn, T.A., Parikh, M., 
Bergman, G.W., Hachamovitch, R., Szulc, M., Kligfield, P.D., 
Okin, P.M., Hahn, R.T., Devereux, R.B., Post, M.R., Hackett, N.R., 
Foster, T., Grasso, T.M., Lesser, M.L., Isom, O.W. and Crystal, R.G. 
1999. Angiogenesis gene therapy: phase I assessment of direct intra-
myocardial administration of an adenovirus vector expressing 
VEGF121 cDNA to individuals with clinically signifi cant severe 
coronary artery disease. Circulation, 100:468–74.
Ruggeri, L., Capanni, M., Martelli, M.F. and Velardi, A. 2001. Cellular 
therapy: exploiting NK cell alloreactivity in transplantation. Curr. 
Opin. Hematol., 8:355–9.
Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., 
Holschermann, H., Yu, J., Corti, R., Mathey, D.G., Hamm, C.W., 
Suselbeck, T., Assmus, B., Tonn, T., Dimmeler, S. and Zeiher, A.M. 
2006. Intracoronary bone marrow-derived progenitor cells in acute 
myocardial infarction. The New England journal of medicine, 
355:1210–21.
Schuh, A., Liehn, E.A., Sasse, A., Hristov, M., Sobota, R., Kelm, M., 
Merx, M.W. and Weber, C. 2007. Transplantation of endothelial pro-
genitor cells improves neovascularization and left ventricular function 
after myocardial infarction in a rat model. Basic Res. Cardiol.
Schuster, M.D., Kocher, A.A., Seki, T., Martens, T.P., Xiang, G., Homma, S. 
and Itescu, S. 2004. Myocardial neovascularization by bone marrow 
angioblasts results in cardiomyocyte regeneration. American journal 
of physiology, 287:525–32.
Scorsin, M., Hagege, A., Vilquin, J.T., Fiszman, M., Marotte, F., Samuel, J.L., 
Rappaport, L., Schwartz, K. and Menasche, P. 2000. Comparison of 
the effects of fetal cardiomyocyte and skeletal myoblast transplanta-
tion on postinfarction left ventricular function. J. Thorac. Cardiovasc. 
Surg., 119:1169–75.
Shake, J.G., Gruber, P.J., Baumgartner, W.A., Senechal, G., Meyers, J., 
Redmond, J.M., Pittenger, M.F. and Martin, B.J. 2002. Mesenchymal 
stem cell implantation in a swine myocardial infarct model: engraft-
ment and functional effects discussion 26. Ann. Thorac. Surg., 
73:1919–25.
Shi, S. and Gronthos, S. 2003. Perivascular niche of postnatal mesenchymal 




Clinical Medicine: Cardiology 2008:2 
Shim, W.S., Jiang, S., Wong, P., Tan, J., Chua, Y.L., Tan, Y.S., Sin, Y.K., 
Lim, C.H., Chua, T., Teh, M., Liu, T.C. and Sim, E. 2004. Ex vivo 
differentiation of human adult bone marrow stem cells into cardio-
myocyte-like cells. Biochemical and biophysical research commu-
nications, 324:481–8.
Shintani, S., Murohara, T., Ikeda, H., Ueno, T., Honma, T., Katoh, A., 
Sasaki, K., Shimada, T., Oike, Y. and Imaizumi, T. 2001. Mobilization 
of endothelial progenitor cells in patients with acute myocardial 
infarction. Circulation, 103:2776–9.
Silva, G.V., Litovsky, S., Assad, J.A., Sousa, A.L., Martin, B.J., Vela, D., 
Coulter, S.C., Lin, J., Ober, J., Vaughn, W.K., Branco, R.V., 
Oliveira, E.M., He, R., Geng, Y.J., Willerson, J.T. and Perin, E.C. 
2005. Mesenchymal stem cells differentiate into an endothelial 
phenotype, enhance vascular density, and improve heart function in 
a canine chronic ischemia model. Circulation, 111:150–6.
Simmons, P.J. and Torok-Storb, B. 1991. Identifi cation of stromal cell 
precursors in human bone marrow by a novel monoclonal antibody 
STRO-1. Blood, 78:55–62.
Smith, R.R., Barile, L., Cho, H.C., Leppo, M.K., Hare, J.M., Messina, E., 
Giacomello, A., Abraham, M.R. and Marban, E. 2007. Regenerative 
potential of cardiosphere-derived cells expanded from percutaneous 
endomyocardial biopsy specimens. Circulation, 115:896–908.
Song, H., Kwon, K., Lim, S., Kang, S.M., Ko, Y.G., Xu, Z., Chung, J.H., 
Kim, B.S., Lee, H., Joung, B., Park, S., Choi, D., Jang, Y., Chung, N.S., 
Yoo, K.J. and Hwang, K.C. 2005. Transfection of mesenchymal stem 
cells with the FGF-2 gene improves their survival under hypoxic 
conditions. Mol. Cells, 19:402–7.
Stamm, C., Westphal, B., Kleine, H.D., Petzsch, M., Kittner, C., Klinge, H., 
Schumichen, C., Nienaber, C.A., Freund, M. and Steinhoff, G. 2003. 
Autologous bone-marrow stem-cell transplantation for myocardial 
regeneration. Lancet, 361:45–6.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. 
and Yamanaka, S. 2007. Induction of pluripotent stem cells from 
adult human fi broblasts by defi ned factors. Cell, 131:861–72.
Tang, Y.L., Tang, Y., Zhang, Y.C., Qian, K., Shen, L. and Phillips, M.I. 
2005a. Improved graft mesenchymal stem cell survival in ischemic 
heart with a hypoxia-regulated heme oxygenase-1 vector. Journal of 
the American College of Cardiology, 46:1339–50.
Tang, Y.L., Zhao, Q., Qin, X., Shen, L., Cheng, L., Ge, J. and Phillips, M.I. 
2005b. Paracrine action enhances the effects of autologous mesen-
chymal stem cell transplantation on vascular regeneration in rat model 
of myocardial infarction. Ann. Thorac. Surg., discussion 36–7, 
80:229–36.
Taylor, D.A., Atkins, B.Z., Hungspreugs, P., Jones, T.R., Reedy, M.C., 
Hutcheson, K.A., Glower, D.D. and Kraus, W.E. 1998. Regenerating 
functional myocardium: improved performance after skeletal myo-
blast transplantation. Nature medicine, 4:929–33.
Terada, N., Hamazaki, T., Oka, M., Hoki, M., Mastalerz, D.M., Nakano, Y., 
Meyer, E.M., Morel, L., Petersen, B.E. and Scott, E.W. 2002. Bone 
marrow cells adopt the phenotype of other cells by spontaneous cell 
fusion. Nature, 416:542–5.
Thompson, R.B., Emani, S.M., Davis, B.H., van den Bos, E.J., Morimoto, Y., 
Craig, D., Glower, D. and Taylor, D.A. 2003. Comparison of intra-
cardiac cell transplantation: autologous skeletal myoblasts versus 
bone marrow cells. Circulation, 108 Suppl, 1:II264–71.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, 
J.J., Marshall, V.S. and Jones, J.M. 1998. Embryonic stem cell lines 
derived from human blastocysts. Science, 282:1145–7.
Toma, C., Pittenger, M.F., Cahill, K.S., Byrne, B.J. and Kessler, P.D. 2002. 
Human mesenchymal stem cells differentiate to a cardiomyocyte 
phenotype in the adult murine heart. Circulation, 105:93–8.
Tse, W.T., Pendleton, J.D., Beyer, W.M., Egalka, M.C. and Guinan, E.C. 2003. 
Suppression of allogeneic T-cell proliferation by human marrow stromal 
cells: implications in transplantation. Transplantation, 75:389–97.
Urbanek, K., Cesselli, D., Rota, M., Nascimbene, A., De Angelis, A., 
Hosoda, T., Bearzi, C., Boni, A., Bolli, R., Kajstura, J., Anversa, P. 
and Leri, A. 2006. Stem cell niches in the adult mouse heart. Proceed-
ings of the National Academy of Sciences of the United States of 
America, 103:9226–31.
Vale, P.R., Losordo, D.W., Milliken, C.E., McDonald, M.C., Gravelin, L.M., 
Curry, C.M., Esakof, D.D., Maysky, M., Symes, J.F. and Isner, J.M. 
2001. Randomized, single-blind, placebo-controlled pilot study of 
catheter-based myocardial gene transfer for therapeutic angiogenesis 
using left ventricular electromechanical mapping in patients with 
chronic myocardial ischemia. Circulation, 103:2138–43.
Weimar, I.S., Miranda, N., Muller, E.J., Hekman, A., Kerst, J.M., de Gast, G.C., 
Gerritsen, W.R. and , . 1998. Hepatocyte growth factor/scatter factor 
(HGF/SF) is produced by human bone marrow stromal cells and 
promotes proliferation, adhesion and survival of human hematopoietic 
progenitor cells (CD34+). Exp. Hematol, 26:885–94.
Wojakowski, W., Kucia, M., Kazmierski, M., Ratajczak, M.Z. and 
Tendera, M. 2007. Circulating stem/progenitor cells in stable ischemic 
heart disease and acute coronary syndromes—relevant reparatory 
mechanism? Heart.
Xu, W., Zhang, X., Qian, H., Zhu, W., Sun, X., Hu, J., Zhou, H. and Chen, Y. 
2004. Mesenchymal stem cells from adult human bone marrow dif-
ferentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med., 
(Maywood), 229:623–31.
Xue, T., Cho, H.C., Akar, F.G., Tsang, S.Y., Jones, S.P., Marban, E., 
Tomaselli, G.F. and Li, R.A. 2005. Functional integration of electri-
cally active cardiac derivatives from genetically engineered human 
embryonic stem cells with quiescent recipient ventricular cardiomyo-
cytes: insights into the development of cell-based pacemakers. 
Circulation, 111:11–20.
Yamanaka, S. and Takahashi, K. 2006. Induction of pluripotent stem cells from 
mouse fi broblast cultures. Tanpakushitsu kakusan koso, 51:2346–51.
Yau, T.M., Fung, K., Weisel, R.D., Fujii, T., Mickle, D.A. and Li, R.K. 2001. 
Enhanced myocardial angiogenesis by gene transfer with transplanted 
cells. Circulation, 104:I218–22.
Young, P.P., Vaughan, D.E. and Hatzopoulos, A.K. 2007. Biologic proper-
ties of endothelial progenitor cells and their potential for cell therapy 
Prog. Cardiovasc. Dis., 49:421–9.
Zannettino, A.C., Paton, S., Arthur, A., Khor, F., Itescu, S., Gimble, J.M. 
and Gronthos, S. 2007. Multipotential human adipose-derived stromal 
stem cells exhibit a perivascular phenotype in vitro and in vivo. J. Cell 
Physiol.
Zhang, M., Mal, N., Kiedrowski, M., Chacko, M., Askari, A.T., Popovic, Z.B., 
Koc, O.N. and Penn, M.S. 2007. SDF-1 expression by mesenchymal 
stem cells results in trophic support of cardiac myocytes after myo-
cardial infarction. Faseb J., 21:3197–207.
 
